DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gantenerumab
Gantenerumab
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
Horizon Scanning Status Report June 2019
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
A Phase III Randomized Trial of Gantenerumab in Prodromal Alzheimer’S Disease Susanne Ostrowitzki1, Robert A
Monoclonal Antibodies As Neurological Therapeutics
(INN) for Biological and Biotechnological Substances
Profile of Gantenerumab and Its Potential in the Treatment of Alzheimer’S Disease
Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current Challenges & Perspectives March 31 - April 1, 2016
INN Working Document 05.179 Update 2011
What Have We Learned from Aducanumab?
Three Essays in Health Economics
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
S00401-015-1484-2.Pdf
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
Aducanumab Produced a Clinically Meaningful Benefit in Association
Roche to Present New Data Demonstrating the Breadth And
Top View
Introduction
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Wo 2010/095940 A2
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Anti-Amyloid-Β Monoclonal Antibodies for Alzheimer's Disease
Gantenerumab: a Novel Human Anti-Aß Antibody Demonstrates
Pharmaceutical Clinical Trials In
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Gantenerumab Reduces Amyloid-Β Plaques in Patients with Prodromal
Com(2010)0397
CLINICAL REVIEW(S) Clinical Review Kevin Krudys, Phd BLA 761178 Aduhelm (Aducanumab)
Engineered Fc Regions for Site-Specific Conjugation
(INN) for Biological and Biotechnological Substances
Gantenerumab Product Analysis
Assessment of the Evolution of Cancer Treatment Therapies
Evaluatepharma World Preview 2015, Outlook to 2020
Download] Conference: 4–7 December 2019; San Diego
Profile of Gantenerumab and Its Potential in the Treatment Of
Computational Analysis for the Rational Design of Anti-Amyloid Beta (A ) Antibodies
Aducanumab for Alzheimer's Disease
Immunotherapy for Alzheimer's Disease